AMR Therapeutics Inc. (AMRTx)
October 18, 2023
Franciscan C
Infectious Diseases
Company Description: Company Name: AMR Therapeutics (AMRTx)
Company Description:
AMRTx is a pioneering biotechnology firm. We are dedicated to revolutionizing post-antibiotics patient care by developing the future anti-bacterial infection drugs.
Key Points:
- Novel "Anti-Infective Drugs": "Anti-infectives" outpace antibiotics, countering drug-resistant mutations with early interventions.
- Diverse Pipeline: Small molecules, peptides, proteins, and monoclonal antibodies.
- Patent Advantage: "Cell shaving" tech, Biopharm+TechBio Platform
Why Invest in AMRTx:
AMRTx aligns with revolutionary anti-infectious innovation with a robust pipeline. We're in resonance with the substantial market demand for innovative solutions amidst the "post-antibiotics era" demand.
Our team merges expertise and entrepreneurship, led by a clear roadmap for pharmaceutic development.
Together, we reshape infectious disease treatment, impacting lives globally.
For information and opportunities, contact us at partner@amr-tx.com.
State
California
Country
United States
Website
http://www.amr-tx.com
CEO/Top Company Official
Dr. Zhiwen Jonathan Zhang, Dr. Gary Li
Lead Product in Development
Our developmental forefront encompasses two categories of lead products:
A) Five small molecule candidates (ATX 1-5) are meticulously designed to directly impede the pivotal bacterial enzyme catalyzing the presentation of virulence factors on the surface of gram-positive bacterial cells. This strategy effectively halts bacterial infections from targeting mammalian cells. ATX-B1, a second-generation small molecule inhibitor, was rapidly designed through an in-house generative AI platform.
B) Three biological candidates (protein AXTPC, peptide AXPN1, and monoclonal antibody AXmAb1) distinctly attenuate bacterial infections by precisely obstructing long-range communication between bacterial and mammalian cells.
These candidates mark pioneering "anti-infective" therapies, especially the biological candidates, which herald a transformative avenue for preventive anti-infectious drugs and vaccine development.
All these candidates have exhibited substantial inhibitory efficacy in both in vitro tests and live cell assays, solidifying their "first-in-kind" status. Our current focus lies in the preclinical stage, leveraging these promising results to advance toward clinical translation.
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
We currently have 8 unlicensed products in our portfolio. These products are in various stages of development and are pending the necessary regulatory approvals.
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)